conoGenetix biosciences GmbH
- Company type:
- Research & Development
- Service Provider
- Year founded:
- Employees (at the site):
- Turnover range:
- <5m EUR
conoGenetix is a privately owned biopharmaceutical company focused on the development of new ion channel selective peptides. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads that modulate ion channel targets - e.g. causatively involved in the generation of autoimmune diseases. Currently, conoGenetix runs a program targeting severe autoimmune disorders like Multiple Sclerosis (MS), Rheumatoid Arthritis (RA) and Vasculitis. Several peptides called cgtx-peptides within this program are in preclinical development.
- Core competencies:
1. Electrophysiological Services
conoGenetix provides electrophysiological services for compound testing and/ or target testing. We test your compound of choice on our ion channel selection. This service is often combined with our Screening Services.
2. Screening Services
In addition to our Electrophysiological Services we are able to adapt your needs to our system. We test your compound libraries on your ion channel target of choice.
3.Grant Support Services
We have execellent experience in grant funding opportunities. Contact us in the forefront of your grant preparation (EC, national or else) and we support you with our expertise.
- Language skills:
- Key Tech / section:
- Biotechnology: Molecular diagnostics for humans
- Biotechnology: Technical services for biotechnology
- Biotechnology: Therapeutic drug development
- Industries NACE:
- 46.18: Agents specialised in the sale of other particular products
- Sales markets - target industries:
- Pharma- und Biotechnologiebranche
- Sales markets - target countries:
- not available
- Cooperation offers:
- not available
- Contact person: